This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparing Bronchodilation of Symbicort With and With Out Valved Holding Chamber (Aerochamber Plus) (WSMR2)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2009 by Western Sky Medical Research.
Recruitment status was:  Recruiting
Information provided by:
Western Sky Medical Research Identifier:
First received: June 4, 2009
Last updated: June 5, 2009
Last verified: June 2009
This study will compare the amount of bronchial tube relaxation from the formoterol medicine contained in the symbicort pMeterd Dose Inhaler( a combination of budesonide ,a steroid, and formoterol, a drug which relaxes the bronchial smooth muscle. The comparison will be using the pMDI in the usual fashion to the pMDIs and a spacer which allows more time for breathing in the medication. Breathing tests will be measured over a 12 hour period for the comparison.

Condition Intervention
Asthma Drug: pMD Symbicort 160/4.5 Drug: Symbicort

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Comparison of the Bronchodilating Activity of Symbicort pMDI 160/4.5 Used in the Conventional Manner and With a Valved Spacer Holding Chamber (Aerochamber Plus)

Further study details as provided by Western Sky Medical Research:

Primary Outcome Measures:
  • 12 hour AUC of FEV-1 [ Time Frame: 12 hours ]

Secondary Outcome Measures:
  • Changes in FEV-1/FVC [ Time Frame: 12 hour ]

Estimated Enrollment: 16
Study Start Date: May 2008
Estimated Study Completion Date: September 2009
Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Conventional First
This group will use pMDI in usual fashion first and cross over to pMDI and valved holding chamber
Drug: pMD Symbicort 160/4.5
The subjects will receive Symbicort pMDI 160/4.5 pMDI used in conventional fashion, and have pulmonary function measured over 12 hours. Secondly on another day, they will receive pMDI using a valved holding chamber
Other Names:
  • Symbicort
  • Aerochamber plus
Experimental: Spacer First
This arm will receive pMDI and Valved holding chamber on fist day. On anther day will receive pMDI in usual fashion. Pulmonary functions wil be measured over 12 hours
Drug: Symbicort
Symbicort 160/4.5 will be administered first first through a valved holding chamber, and on another day in the conventional fashion. Pulmonary functions will be measured ove r12 hours
Other Name: Aerochamber plus


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Asthma with 15% or more increase in FEV-1 after 180-260 mcg of albuterol pMDI

Exclusion Criteria:

  • Any illness or condition which might place subject at risk in the study;e.g. some cardiovascular disorders Inability to understand and sign informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00915538

Contact: Catherine Posey, CCRC 915-544-2557
Contact: Lyndon E Mansfield, MD CPI 915-544-2557

United States, Texas
Western Sky Medical Research Recruiting
El Paso, Texas, United States, 79903
Contact: Catherine Posey, CCRC    915-544-2557   
Contact: Lyndon E Mansfield, MD CPI    915-544-2557   
Principal Investigator: Lyndon E Mansfield, MD CPI         
Sponsors and Collaborators
Western Sky Medical Research
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Lyndon E. Mansfield, Western Sky Medical Research Identifier: NCT00915538     History of Changes
Other Study ID Numbers: WSMR 2008-2
Study First Received: June 4, 2009
Last Updated: June 5, 2009

Keywords provided by Western Sky Medical Research:

Additional relevant MeSH terms:
Budesonide, Formoterol Fumarate Drug Combination
Anti-Asthmatic Agents
Respiratory System Agents processed this record on September 20, 2017